LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

114.64 16.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

98.26

Max

114.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

-112M

Verkäufe

20M

302M

EPS

-0.45

Gewinnspanne

-37.152

Angestellte

2,490

EBITDA

18M

-101M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+30.82% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

598M

13B

Vorheriger Eröffnungskurs

97.92

Vorheriger Schlusskurs

114.64

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Mai 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. Mai 2026, 22:52 UTC

Wichtige Markttreiber

Osisko Shares Fall on Planned Convertible Notes Offering

20. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. Mai 2026, 23:44 UTC

Ergebnisse

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. Mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. Mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. Mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. Mai 2026, 23:14 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. Mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. Mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. Mai 2026, 22:10 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. Mai 2026, 22:00 UTC

Ergebnisse

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. Mai 2026, 21:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. Mai 2026, 21:27 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. Mai 2026, 21:20 UTC

Ergebnisse

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. Mai 2026, 21:19 UTC

Ergebnisse

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. Mai 2026, 21:18 UTC

Ergebnisse

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. Mai 2026, 21:16 UTC

Ergebnisse

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

30.82% Vorteil

12-Monats-Prognose

Durchschnitt 128.45 USD  30.82%

Hoch 150 USD

Tief 95 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

15

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat